Clinical trialNo phase (not a drug trial)Unknown
CART Therapy in Digestive System Tumors
Chimeric Antigen Receptor T Cells (CART) Therapy in GUCY2C Positive Digestive System Tumors
- Outcome
- Outcome unknown
- Cell product
- CAR-T cells
CART Therapy in Digestive System Tumors
- Target antigen
- GUCY2C
Chimeric Antigen Receptor T Cells (CART) Therapy in GUCY2C Positive Digestive System Tumors
- Phase
- No phase (not a drug trial)
- Status
- Unknown
- Study type
- Interventional
- Start
- March 2021
- Listed end
- March 2026
- Enrollment
- 20 participants
- Sites
- 1
- Primary outcomes
- Number of participants with CAR-T treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: 24 months ]
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 3 March 2021
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Chimeric Antigen Receptor T Cells (CART) Therapy in GUYC2C postive Digestive system tumors, include colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, adenocarcinoma of esophagus, cancer of the esophagogastric junction. Ict-gc is an open, single-center study to evaluate the safety and efficacy of CAR-T-targeted therapy in patients with advanced gastrointestinal tumors.
Detailed description public domain (ClinicalTrials.gov)
The primary objective of phase 1 is to evaluate the safety of CART regimens. The primary objective of phase 2 is to evaluate the efficacy of CART, as measured by objective response rate in subjects with colorectal cancer. Secondary objectives will include assessing the safety and tolerability of CART and additional efficacy endpoints.
Intervention public domain (ClinicalTrials.gov)
Biological: gucy2c cart cells. Patients with advanced malignant gastrointestinal tumors were injected with CART cells
Arm public domain (ClinicalTrials.gov)
Patients with late malignant digestive tract tumor (experimental): Patients with late malignant digestive tract tumor, for example metastatic colorectal cancer, pancreatic cancer, gastric cancer and so on. because of this is a open, single arm trail, there is no control group.